These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34391396)

  • 21. Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011.
    Wang LJ; Lee SY; Yuan SS; Yang CJ; Yang KC; Huang TS; Chou WJ; Chou MC; Lee MJ; Lee TL; Shyu YC
    Epidemiol Psychiatr Sci; 2017 Dec; 26(6):624-634. PubMed ID: 27435692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
    Song I; Lee MS; Lee EK; Shin JY
    Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007.
    Schubert I; Köster I; Lehmkuhl G
    Dtsch Arztebl Int; 2010 Sep; 107(36):615-21. PubMed ID: 20948775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative Efficacy of Methylphenidate and Atomoxetine on Social Adjustment in Youths with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Shih HH; Pan YL; Lin HY; Gau SS
    J Child Adolesc Psychopharmacol; 2020 Apr; 30(3):148-158. PubMed ID: 31794244
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q; Zhang H; Fang Q; Qin L
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Efficacy of Methylphenidate and Atomoxetine on Emotional and Behavioral Problems in Youths with Attention-Deficit/Hyperactivity Disorder.
    Shih HH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2019 Feb; 29(1):9-19. PubMed ID: 30457349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence, incidence and persistence of ADHD drug use in Japan.
    Okumura Y; Usami M; Okada T; Saito T; Negoro H; Tsujii N; Fujita J; Iida J
    Epidemiol Psychiatr Sci; 2019 Dec; 28(6):692-696. PubMed ID: 29804548
    [No Abstract]   [Full Text] [Related]  

  • 31. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of attention-deficit/hyperactivity disorder in clinical practice. A retrospective study].
    López-López A; Poch-Olivé ML; López-Pisón J; Cardo-Jalón E;
    Medicina (B Aires); 2019; 79(Suppl 1):68-71. PubMed ID: 30776283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADHD in Germany: Trends in Diagnosis and Pharmacotherapy.
    Bachmann CJ; Philipsen A; Hoffmann F
    Dtsch Arztebl Int; 2017 Mar; 114(9):141-148. PubMed ID: 28351466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of the Preschool ADHD Treatment Study (PATS) Children Growing Up.
    Vitiello B; Lazzaretto D; Yershova K; Abikoff H; Paykina N; McCracken JT; McGough JJ; Kollins SH; Greenhill LL; Wigal S; Wigal T; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):550-6. PubMed ID: 26088659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy for ADHD in children and adolescents: A summary and overview of different European guidelines.
    Van Vyve L; Dierckx B; Lim CG; Danckaerts M; Koch BCP; Häge A; Banaschewski T
    Eur J Pediatr; 2024 Mar; 183(3):1047-1056. PubMed ID: 38095716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in use of attention deficit hyperactivity disorder medication among children and adolescents in Scandinavia in 2010-2020.
    Sørensen AMS; Wesselhöeft R; Andersen JH; Reutfors J; Cesta CE; Furu K; Hartz I; Rasmussen L
    Eur Child Adolesc Psychiatry; 2023 Oct; 32(10):2049-2056. PubMed ID: 35831669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.